Standard Biotools (LAB)
Standard Biotools on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.5M
Short interest
settlement 2026-09-30
2.7
Days to cover
+1.3 days vs prior
38.1%
Short share of volume
2026-10-23
463
Fails to deliver
settlement 2026-09-17
Wed 28 Oct
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in LAB is 2,520,686 shares, down 458,342 shares over the last month. Over the last 48 readings it ranged from 2,213,551 shares (15 July 2026) to 21,331,304 shares (15 October 2024). The latest reading sits at the bottom of that range. At the reported average volume of 925K shares a day that is 2.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/lab" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 2,520,686 | -2.8% | 925,491 | 2.72 |
| 2026-09-15 | 2,593,308 | -12.9% | 1,803,273 | 1.44 |
| 2026-08-31 | 2,979,028 | +23.9% | 1,702,005 | 1.75 |
| 2026-08-14 | 2,405,258 | -10.7% | 1,113,541 | 2.16 |
| 2026-07-31 | 2,694,489 | +21.7% | 2,015,651 | 1.34 |
| 2026-07-15 | 2,213,551 | -35.4% | 3,059,750 | 1.00 |
| 2026-06-30 | 3,425,003 | -65.8% | 6,850,088 | 1.00 |
| 2026-06-15 | 10,029,339 | -23.6% | 4,947,644 | 2.03 |
| 2026-05-29 | 13,127,631 | +1.6% | 2,222,425 | 5.91 |
| 2026-05-15 | 12,920,309 | +9.3% | 1,849,667 | 6.99 |
| 2026-04-30 | 11,821,128 | +39.4% | 2,783,179 | 4.25 |
| 2026-04-15 | 8,479,342 | -17.8% | 3,556,516 | 2.38 |
| 2026-03-31 | 10,319,954 | +24.6% | 1,846,849 | 5.59 |
| 2026-03-13 | 8,281,198 | -18.5% | 3,266,118 | 2.54 |
| 2026-02-27 | 10,159,609 | -3.2% | 1,710,284 | 5.94 |
| 2026-02-13 | 10,493,665 | +7.2% | 1,306,199 | 8.03 |
| 2026-01-30 | 9,788,254 | -4.0% | 1,064,308 | 9.20 |
| 2026-01-15 | 10,191,929 | -1.1% | 1,945,334 | 5.24 |
| 2025-12-31 | 10,301,667 | -1.7% | 1,672,914 | 6.16 |
| 2025-12-15 | 10,478,841 | -4.0% | 1,215,818 | 8.62 |
| 2025-11-28 | 10,921,071 | -7.9% | 2,803,089 | 3.90 |
| 2025-11-14 | 11,856,210 | +3.5% | 1,623,116 | 7.30 |
| 2025-10-31 | 11,453,426 | -3.3% | 1,792,419 | 6.39 |
| 2025-10-15 | 11,839,646 | -1.7% | 1,370,677 | 8.64 |
| 2025-09-30 | 12,049,852 | +0.5% | 1,196,398 | 10.07 |
| 2025-09-15 | 11,992,813 | -1.4% | 1,201,220 | 9.98 |
| 2025-08-29 | 12,169,060 | -3.0% | 1,159,223 | 10.50 |
| 2025-08-15 | 12,538,712 | +4.4% | 1,191,441 | 10.52 |
| 2025-07-31 | 12,009,245 | -2.6% | 1,544,401 | 7.78 |
| 2025-07-15 | 12,335,128 | -4.2% | 1,654,644 | 7.45 |
| 2025-06-30 | 12,873,448 | -20.3% | 4,066,347 | 3.17 |
| 2025-06-13 | 16,159,588 | -5.2% | 955,793 | 16.91 |
| 2025-05-30 | 17,042,645 | -2.6% | 1,602,634 | 10.63 |
| 2025-05-15 | 17,493,417 | -5.1% | 1,560,108 | 11.21 |
| 2025-04-30 | 18,440,306 | +6.8% | 782,315 | 23.57 |
| 2025-04-15 | 17,261,965 | -2.4% | 1,410,835 | 12.24 |
| 2025-03-31 | 17,683,207 | +12.4% | 1,298,836 | 13.61 |
| 2025-03-14 | 15,728,051 | +11.0% | 1,998,852 | 7.87 |
| 2025-02-28 | 14,165,972 | +5.0% | 2,778,877 | 5.10 |
| 2025-02-14 | 13,495,961 | +5.0% | 1,957,291 | 6.90 |
| 2025-01-31 | 12,849,731 | -3.6% | 1,758,778 | 7.31 |
| 2025-01-15 | 13,324,142 | -1.5% | 1,802,025 | 7.39 |
| 2024-12-31 | 13,523,264 | +1.6% | 1,458,616 | 9.27 |
| 2024-12-13 | 13,310,534 | -3.3% | 1,306,916 | 10.18 |
| 2024-11-29 | 13,767,237 | -6.2% | 2,032,385 | 6.77 |
| 2024-11-15 | 14,682,662 | -24.9% | 2,419,413 | 6.07 |
| 2024-10-31 | 19,540,970 | -8.4% | 2,126,488 | 9.19 |
| 2024-10-15 | 21,331,304 | +0.2% | 1,042,948 | 20.45 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of LAB volume is 38.1%, down 48.9 points over the last five sessions. Over the last 30 readings it ranged from 22.4% (14 September 2026) to 87.0% (16 October 2026). The latest reading is 12.0 points below the 30-session average of 50.1%, on 390K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 149K | 390K | 38.1% | 6,400 |
| 2026-10-22 | 131K | 577K | 22.7% | 0 |
| 2026-10-21 | 134K | 206K | 65.0% | 0 |
| 2026-10-20 | 128K | 180K | 71.5% | 0 |
| 2026-10-19 | 113K | 152K | 74.8% | 0 |
| 2026-10-16 | 372K | 428K | 87.0% | 0 |
| 2026-10-15 | 178K | 307K | 58.1% | 0 |
| 2026-10-14 | 67K | 178K | 37.4% | 0 |
| 2026-10-13 | 159K | 229K | 69.6% | 0 |
| 2026-10-12 | 227K | 310K | 73.4% | 0 |
| 2026-10-09 | 140K | 358K | 39.1% | 0 |
| 2026-10-08 | 497K | 862K | 57.7% | 0 |
| 2026-10-07 | 287K | 720K | 39.9% | 0 |
| 2026-10-06 | 286K | 734K | 39.0% | 0 |
| 2026-10-05 | 299K | 616K | 48.5% | 15,900 |
| 2026-10-02 | 109K | 404K | 26.9% | 524 |
| 2026-10-01 | 322K | 632K | 51.0% | 0 |
| 2026-09-30 | 550K | 1.1M | 49.4% | 600 |
| 2026-09-29 | 62K | 83K | 74.5% | 0 |
| 2026-09-28 | 74K | 283K | 26.1% | 7,000 |
| 2026-09-25 | 56K | 163K | 34.2% | 0 |
| 2026-09-24 | 184K | 373K | 49.5% | 0 |
| 2026-09-23 | 236K | 351K | 67.1% | 0 |
| 2026-09-22 | 433K | 805K | 53.8% | 0 |
| 2026-09-21 | 108K | 248K | 43.6% | 0 |
| 2026-09-18 | 485K | 797K | 60.9% | 415 |
| 2026-09-17 | 128K | 316K | 40.6% | 0 |
| 2026-09-16 | 179K | 467K | 38.3% | 0 |
| 2026-09-15 | 228K | 532K | 42.9% | 0 |
| 2026-09-14 | 91K | 406K | 22.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 17 September 2026, the fails-to-deliver balance in LAB is 463 shares, up 452 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (11 August 2026) to 224,733 shares (14 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-17 | 463 | $0.71 | $329 |
| 2026-09-15 | 11 | $0.70 | $8 |
| 2026-09-11 | 228 | $0.69 | $157 |
| 2026-09-09 | 67 | $0.69 | $46 |
| 2026-09-08 | 5,132 | $0.69 | $4K |
| 2026-08-31 | 7,767 | $0.64 | $5K |
| 2026-08-13 | 800 | $0.79 | $632 |
| 2026-08-11 | 2 | $0.79 | $2 |
| 2026-08-05 | 1,003 | $0.82 | $822 |
| 2026-08-04 | 4,000 | $0.87 | $3K |
| 2026-08-03 | 7 | $0.87 | $6 |
| 2026-07-31 | 320 | $0.90 | $288 |
| 2026-07-30 | 320 | $0.87 | $278 |
| 2026-06-26 | 31,325 | $0.74 | $23K |
| 2026-06-22 | 39,634 | $0.83 | $33K |
| 2026-06-18 | 24,924 | $0.81 | $20K |
| 2026-06-17 | 57,667 | $0.83 | $48K |
| 2026-06-16 | 160 | $0.85 | $136 |
| 2026-06-15 | 1,429 | $0.89 | $1K |
| 2026-06-12 | 228 | $0.91 | $207 |
| 2026-06-10 | 21,277 | $0.89 | $19K |
| 2026-06-05 | 3,839 | $1.27 | $5K |
| 2026-06-04 | 2,611 | $1.14 | $3K |
| 2026-05-28 | 686 | $1.06 | $727 |
| 2026-05-19 | 66,657 | $0.99 | $66K |
| 2026-05-18 | 55,907 | $0.98 | $55K |
| 2026-05-15 | 6,686 | $1.00 | $7K |
| 2026-05-14 | 224,733 | $1.01 | $227K |
| 2026-05-07 | 64,777 | $0.97 | $63K |
| 2026-05-05 | 47,243 | $0.94 | $44K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for LAB in the last 90 days. The most recent filings are listed below. Latest filing: Mackay Sean (SVP & Chief Business Officer) on 2026-08-20.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Mackay Sean | SVP & Chief Business Officer | Tax withholding | 26K | $0.67 | $17K | 1.5M |
| 2026-08-20 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 28K | $0.67 | $19K | 2.5M |
| 2026-08-20 | Egholm Michael | President & CEO | Tax withholding | 98K | $0.67 | $66K | 6.1M |
| 2026-08-03 | Egholm Michael | President & CEO | Tax withholding | 363K | $0.87 | $315K | 6.2M |
| 2026-07-23 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 202K | $0.90 | $181K | 2.6M |
| 2026-06-20 | Mackay Sean | SVP & Chief Business Officer | Grant | 500K | $0.00 | $0 | 1.5M |
| 2026-06-18 | HIBBS KATHY L | Director | Grant | 99K | $0.00 | $0 | 237K |
| 2026-06-18 | ELOI FENEL M | Director | Grant | 99K | $0.00 | $0 | 335K |
| 2026-06-18 | Cox Troy | Director | Grant | 99K | $0.00 | $0 | 476K |
| 2026-06-18 | Casdin Eli | Director,TenPercentOwner | Grant | 99K | $0.00 | $0 | 3.1M |
| 2026-06-18 | Witney Frank | Director | Grant | 99K | $0.00 | $0 | 310K |
| 2026-06-18 | Carey Thomas D. | Director | Grant | 99K | $0.00 | $0 | 344K |
| 2026-05-20 | Mackay Sean | SVP & Chief Business Officer | Tax withholding | 26K | $1.00 | $26K | 1.0M |
| 2026-05-20 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 19K | $1.00 | $19K | 2.8M |
| 2026-05-20 | Egholm Michael | President & CEO | Tax withholding | 98K | $1.00 | $98K | 6.6M |
| 2026-04-06 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 21K | $0.91 | $19K | 2.8M |
| 2026-04-06 | Kim Hanjoon Alex | Chief Financial Officer | Exercise or conversion | 70K | $0.00 | $0 | 2.8M |
| 2026-04-06 | Egholm Michael | President & CEO | Tax withholding | 95K | $0.91 | $86K | 6.7M |
| 2026-04-06 | Egholm Michael | President & CEO | Exercise or conversion | 197K | $0.00 | $0 | 6.8M |
| 2026-03-20 | Mackay Sean | SVP & Chief Business Officer | Grant | 272K | $0.00 | $0 | 1.0M |
| 2026-03-20 | Kim Hanjoon Alex | Chief Financial Officer | Grant | 323K | $0.00 | $0 | 2.7M |
| 2026-03-20 | Egholm Michael | President & CEO | Grant | 1.0M | $0.00 | $0 | 6.6M |
| 2026-02-26 | Cox Troy | Director | Grant | 57K | $1.17 | $67K | 377K |
| 2026-02-26 | Casdin Eli | Director, 10% owner | Grant | 53K | $1.17 | $62K | 3.0M |
| 2026-02-26 | Carey Thomas D. | Director | Grant | 51K | $1.17 | $60K | 245K |
| 2026-02-23 | Mackay Sean | SVP & Chief Business Officer | Tax withholding | 20K | $1.15 | $23K | 760K |
| 2026-02-23 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 13K | $1.15 | $15K | 2.4M |
| 2026-02-23 | Egholm Michael | President & CEO | Tax withholding | 66K | $1.15 | $76K | 5.6M |
| 2025-12-04 | CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC | Director | Buy | 150K | $1.45 | $218K | 72.1M |
| 2025-12-04 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 150K | $1.45 | $217K | 72.1M |
| 2025-12-03 | CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC | Director | Buy | 75K | $1.44 | $108K | 72.0M |
| 2025-12-03 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 75K | $1.44 | $108K | 72.0M |
| 2025-12-02 | CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC | Director | Buy | 125K | $1.42 | $178K | 71.9M |
| 2025-12-02 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 125K | $1.42 | $178K | 71.9M |
| 2025-11-25 | Casdin Partners GP, LLC | Director,TenPercentOwner | Buy | 7.5M | $1.30 | $9.8M | 71.8M |
| 2025-11-25 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 7.5M | $1.30 | $9.8M | 71.8M |
| 2025-11-24 | Casdin Partners GP, LLC | Director,TenPercentOwner | Buy | 150K | $1.43 | $215K | 64.2M |
| 2025-11-24 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 150K | $1.43 | $215K | 64.2M |
| 2025-11-20 | Casdin Eli | Director,TenPercentOwner | Buy | 450K | $1.30 | $585K | 64.0M |
| 2025-11-20 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 450K | $1.30 | $586K | 64.0M |
| 2025-11-20 | Mackay Sean | SVP & Chief Business Officer | Tax withholding | 20K | $1.28 | $25K | 780K |
| 2025-11-20 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 13K | $1.28 | $16K | 2.4M |
| 2025-11-20 | Egholm Michael | President & CEO | Tax withholding | 64K | $1.28 | $81K | 5.6M |
| 2025-11-19 | Casdin Eli | Director,TenPercentOwner | Buy | 350K | $1.28 | $448K | 63.6M |
| 2025-11-19 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 350K | $1.28 | $449K | 63.6M |
| 2025-11-18 | Casdin Eli | Director,TenPercentOwner | Buy | 275K | $1.23 | $338K | 63.3M |
| 2025-11-18 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 275K | $1.23 | $339K | 63.3M |
| 2025-11-17 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 225K | $1.22 | $276K | 63.0M |
| 2025-11-14 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 250K | $1.24 | $310K | 62.8M |
| 2025-11-13 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 450K | $1.20 | $541K | 62.5M |
| 2025-11-12 | Casdin Partners GP, LLC | Director,TenPercentOwner | Buy | 375K | $1.19 | $446K | 62.0M |
| 2025-11-12 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 375K | $1.19 | $446K | 62.0M |
| 2025-11-11 | Casdin Partners GP, LLC | Director,TenPercentOwner | Buy | 300K | $1.20 | $360K | 61.7M |
| 2025-11-11 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 300K | $1.20 | $359K | 61.7M |
| 2025-11-10 | Casdin Partners GP, LLC | Director,TenPercentOwner | Buy | 275K | $1.17 | $322K | 61.4M |
| 2025-11-10 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 275K | $1.17 | $322K | 61.4M |
| 2025-11-07 | Casdin Partners GP, LLC | Director,TenPercentOwner | Buy | 225K | $1.12 | $252K | 61.1M |
| 2025-11-07 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 225K | $1.12 | $253K | 61.1M |
| 2025-09-09 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 100K | $1.29 | $129K | 60.9M |
| 2025-09-04 | Casdin Eli | Director,TenPercentOwner | Buy | 250K | $1.28 | $320K | 60.8M |
| 2025-09-04 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 250K | $1.28 | $319K | 60.8M |
| 2025-09-03 | Casdin Eli | Director,TenPercentOwner | Buy | 250K | $1.27 | $318K | 60.5M |
| 2025-09-03 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 250K | $1.27 | $316K | 60.5M |
| 2025-08-26 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 125K | $1.26 | $158K | 60.3M |
| 2025-08-25 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 200K | $1.24 | $248K | 60.1M |
| 2025-08-22 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 200K | $1.26 | $253K | 60.0M |
| 2025-08-20 | Mackay Sean | SVP & Chief Business Officer | Tax withholding | 20K | $1.27 | $25K | 799K |
| 2025-08-20 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 13K | $1.27 | $16K | 2.4M |
| 2025-08-20 | Egholm Michael | President & CEO | Tax withholding | 55K | $1.27 | $70K | 5.7M |
| 2025-08-15 | Casdin Eli | Director,TenPercentOwner | Buy | 150K | $1.22 | $183K | 59.8M |
| 2025-08-15 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 150K | $1.22 | $183K | 59.8M |
| 2025-08-14 | Casdin Eli | Director,TenPercentOwner | Buy | 133K | $1.21 | $161K | 59.6M |
| 2025-08-14 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 133K | $1.21 | $162K | 59.6M |
| 2025-08-13 | Casdin Eli | Director,TenPercentOwner | Buy | 75K | $1.31 | $98K | 59.5M |
| 2025-08-13 | Casdin Partners Master Fund, L.P. | Director, 10% owner | Buy | 75K | $1.31 | $98K | 59.5M |
| 2025-08-01 | Kim Hanjoon Alex | Chief Financial Officer | Grant | 1.5M | $0.00 | $0 | 2.4M |
| 2025-08-01 | Egholm Michael | President & CEO | Grant | 3.0M | $0.00 | $0 | 5.7M |
| 2025-06-20 | Witney Frank | Director | Grant | 95K | $0.00 | $0 | 211K |
| 2025-06-20 | HIBBS KATHY L | Director | Grant | 95K | $0.00 | $0 | 138K |
| 2025-06-20 | ELOI FENEL M | Director | Grant | 95K | $0.00 | $0 | 236K |
| 2025-06-20 | Cox Troy | Director | Grant | 95K | $0.00 | $0 | 256K |
| 2025-06-20 | Casdin Eli | Director, 10% owner | Grant | 95K | $0.00 | $0 | 2.9M |
| 2025-06-20 | Carey Thomas D. | Director | Grant | 95K | $0.00 | $0 | 194K |
| 2025-05-28 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 3K | $1.09 | $3K | 928K |
| 2025-05-28 | Egholm Michael | President & CEO | Tax withholding | 10K | $1.09 | $11K | 2.7M |
| 2025-05-28 | Mackay Sean | SVP & Chief Business Officer | Tax withholding | 24K | $1.09 | $26K | 819K |
| 2025-05-23 | Egholm Michael | President & CEO | Sell | 5K | $0.94 | $5K | 2.7M |
| 2025-05-23 | Mackay Sean | SVP & Chief Business Officer | Sell | 13K | $0.94 | $12K | 843K |
| 2025-05-23 | Kim Hanjoon Alex | Chief Financial Officer | Sell | 1K | $0.94 | $1K | 930K |
| 2025-05-22 | Mackay Sean | SVP & Chief Business Officer | Sell | 13K | $1.00 | $13K | 856K |
| 2025-05-22 | Egholm Michael | President & CEO | Sell | 5K | $1.00 | $5K | 2.7M |
| 2025-05-22 | Kim Hanjoon Alex | Chief Financial Officer | Sell | 1K | $1.00 | $1K | 932K |
| 2025-05-21 | Kim Hanjoon Alex | Chief Financial Officer | Sell | 1K | $1.03 | $1K | 933K |
| 2025-05-21 | Egholm Michael | President & CEO | Sell | 5K | $1.03 | $5K | 2.8M |
| 2025-05-21 | Mackay Sean | SVP & Chief Business Officer | Sell | 13K | $1.03 | $13K | 869K |
| 2025-05-20 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 6K | $1.05 | $7K | 934K |
| 2025-05-20 | Egholm Michael | President & CEO | Tax withholding | 18K | $1.05 | $19K | 2.8M |
| 2025-04-04 | Kim Hanjoon Alex | Chief Financial Officer | Exercise or conversion | 70K | $0.00 | $0 | 962K |
| 2025-04-04 | Kim Hanjoon Alex | Chief Financial Officer | Tax withholding | 21K | $1.07 | $23K | 941K |
| 2025-04-04 | Egholm Michael | President & CEO | Tax withholding | 58K | $1.07 | $62K | 2.8M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON20 holders report 5% or more of LAB in their latest filing, 14 on Schedule 13D (active intent). The largest reported stake is Eli Casdin at 23.9% of the class (93,845,778 shares), filed 2026-06-09 for an event on 2026-06-06.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 2 | MAK Capital Fund LPpartnership | 28.8M | 7.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Kaufman Michael Aindividual | 28.8M | 7.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | MAK CAPITAL ONE LLCinvestment adviser | 28.8M | 7.3% | 2026-06-30 |
| 2026-08-14 | 13G | JOHN HELMERSindividual | 23.5M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G | LONG FOCUS CAPITAL MANAGEMENT, LLCinvestment adviser | 23.5M | 6.0% | 2026-06-30 |
| 2026-07-30 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 7.9M | 2.0% | 2026-06-30 |
| 2026-06-12 | 13D | Shabet Rose Sharonindividual | 58.7M | 15.0% | 2026-06-06 |
| 2026-06-12 | 13D | HALVORSEN OLE ANDREASindividual | 58.7M | 15.0% | 2026-06-06 |
| 2026-06-12 | 13D | VIKING GLOBAL INVESTORS LPpartnership | 58.7M | 15.0% | 2026-06-06 |
| 2026-06-12 | 13D | Viking Global Opportunities Parent GP LLCother entity | 58.7M | 15.0% | 2026-06-06 |
| 2026-06-12 | 13D | Viking Global Opportunities Illiquid Investments Sub-Master LPpartnership | 39.3M | 10.1% | 2026-06-06 |
| 2026-06-12 | 13D | Viking Global Opportunities Portfolio GP LLCother entity | 39.3M | 10.1% | 2026-06-06 |
| 2026-06-12 | 13D | Viking Global Opportunities GP LLCother entity | 39.3M | 10.1% | 2026-06-06 |
| 2026-06-12 | 13D | Viking Global Opportunities Drawdown Portfolio GP LLCother entity | 19.4M | 5.0% | 2026-06-06 |
| 2026-06-12 | 13D | Viking Global Opportunities Drawdown (Aggregator) LPpartnership | 19.4M | 5.0% | 2026-06-06 |
| 2026-06-12 | 13D | Viking Global Opportunities Drawdown GP LLCother entity | 19.4M | 5.0% | 2026-06-06 |
| 2026-06-09 | 13D/Ano. 8 | Eli Casdinindividual, parent holding company | 93.8M | 23.9% | 2026-06-06 |
| 2026-06-09 | 13D/Ano. 8 | Casdin Capital, LLCinvestment adviser | 88.8M | 22.7% | 2026-06-06 |
| 2026-06-09 | 13D/Ano. 8 | Casdin Partners GP, LLCother entity | 72.1M | 18.5% | 2026-06-06 |
| 2026-06-09 | 13D/Ano. 8 | Casdin Partners Master Fund, L.P.partnership | 72.1M | 18.5% | 2026-06-06 |
| 2026-06-09 | 13D/Ano. 8 | Casdin Private Growth Equity Fund II, L.P.partnership | 13.9M | 3.6% | 2026-06-06 |
| 2026-06-09 | 13D/Ano. 8 | Casdin Private Growth Equity Fund II GP, LLCother entity | 13.9M | 3.6% | 2026-06-06 |
| 2026-05-15 | 13G/Ano. 1 | Michael A. Kaufmanindividual | 26.2M | 6.7% | 2026-03-31 |
13F holders
Tracked managers holding LAB at their latest 13F. JSON7 of the 30 tracked managers held LAB at their latest 13F, $57.9M in total at quarter-end prices. Viking Global Investors is the largest at $48.3M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Viking Global Investors | 2026-06-30 | 58.7M | $48.3M | 0.14% | 0 |
| Millennium Management | 2026-06-30 | 3.5M | $2.9M | 0.00% | +1.4M |
| D. E. Shaw & Co. | 2026-06-30 | 2.8M | $2.3M | 0.00% | +2.6M |
| Citadel Advisors | 2026-06-30 | 2.3M | $1.9M | 0.00% | +1.1M |
| AQR Capital Management | 2026-06-30 | 1.4M | $1.1M | 0.00% | +426K |
| Renaissance Technologies | 2026-06-30 | 992K | $816K | 0.00% | new |
| Point72 Asset Management | 2026-06-30 | 708K | $582K | 0.00% | +663K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Standard Biotools reported revenue of $20.1M, down 7.6% from the same quarter a year earlier, and net loss of $26.8M (-0.07 diluted EPS). In FY 2025 it generated -$74.3M of operating cash flow.
- Cash
- $270.0M
- Equity
- $540.0M
- Total assets
- $627.2M
- Shares outstanding
- 392,578,808
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $20.1M | -$26.8M | -133.1% | -0.07 |
| Q1 FY 2026 | 2026-03-31 | $21.1M | $127.1M | 600.9% | 0.33 |
| Q4 FY 2025derived | 2025-12-31 | $23.8M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $19.6M | -$34.7M | -177.4% | -0.09 |
| Q2 FY 2025 | 2025-06-30 | $21.8M | -$33.5M | -153.7% | -0.09 |
| Q1 FY 2025 | 2025-03-31 | $20.2M | -$26.0M | -128.7% | -0.07 |
| Q4 FY 2024derived | 2024-12-31 | $890K | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $22.1M | -$26.9M | -122.0% | -0.07 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $85.3M | -$74.9M | -$74.3M | $8.3M | $0 | n/a |
| FY 2024 | 2024-12-31 | $91.0M | -$138.9M | -$143.5M | $8.4M | $40.5M | n/a |
| FY 2023 | 2023-12-31 | $106.3M | -$74.7M | -$43.3M | $2.8M | $5.4M | n/a |
| FY 2022 | 2022-12-31 | $97.9M | -$190.1M | -$89.4M | $3.8M | $563K | n/a |
| FY 2021 | 2021-12-31 | $130.6M | -$59.2M | -$44.1M | $13.3M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Standard Biotools in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Standard Biotools (LAB), SEC CIK 1162194, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-17.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-20.JSON and CSV
- Company record
- EDGAR filing index for CIK 1162194Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of LAB is sold short?
2,520,686 shares were held short at the 2026-09-30 settlement, 2.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is LAB's daily short volume?
On 2026-10-23, 148,621 of the 390,136 LAB shares reported to FINRA were sold short, 38.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does LAB have fails to deliver?
The SEC's latest file shows 463 LAB shares failed to deliver at settlement 2026-09-17. Fails are reported per settlement date and published twice a month with a lag.
Are LAB insiders buying or selling?
No open-market insider trades were reported for LAB in the last 90 days. The most recent filings are listed below. Latest filing: Mackay Sean (SVP & Chief Business Officer) on 2026-08-20.
Who owns 5% or more of LAB?
20 holders report 5% or more of LAB in their latest filing, 14 on Schedule 13D (active intent). The largest reported stake is Eli Casdin at 23.9% of the class (93,845,778 shares), filed 2026-06-09 for an event on 2026-06-06.
What did LAB report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Standard Biotools reported revenue of $20.1M, down 7.6% from the same quarter a year earlier, and net loss of $26.8M (-0.07 diluted EPS). In FY 2025 it generated -$74.3M of operating cash flow.
Which tracked 13F managers own LAB?
7 of the 30 tracked 13F managers held LAB shares at their latest filing, $57.9M in all. The largest: Andreas Halvorsen's Viking Global Investors (58.7M shares, $48.3M), Izzy Englander's Millennium Management (3.5M shares, $2.9M), D. E. Shaw & Co. (2.8M shares, $2.3M), Ken Griffin's Citadel Advisors (2.3M shares, $1.9M), Cliff Asness's AQR Capital Management (1.4M shares, $1.1M), Renaissance Technologies (992K shares, $816K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.